Radboud university medical center

What Radboud university medical center does

Radboud university medical center (Radboudumc) is a public academic medical center in Nijmegen, Netherlands, founded in 1951 and affiliated with Radboud University on a joint campus. The center operates a tertiary care hospital together with the Amalia Children's Hospital (one of eight academic children's hospitals in the Netherlands), serving approximately 30,000 inpatients and 400,000 outpatients annually. Radboudumc is staffed by 13,000 employees across clinical, research, and educational roles.

The institution generates revenue primarily through regulated Dutch Diagnosis Treatment Combinations (DBCs) billed under the national health insurance framework, supplemented by research grants and competitive funding (Leducq, EU, patient foundations). Its go-to-market is sales-led via referrals from general practitioners and regional hospitals, with research-driven acquisition through collaborations with Dutch university medical centers (notably Maastricht UMC+) and international consortia. Customer segments include patients with rare genetic disorders (the core focus for its long-read sequencing program), pediatric patients and families, infectious disease cases, and tertiary referral patients from across the Netherlands.

Radboudumc's most differentiated technology is clinical-grade long-read genome sequencing, the first deployment at scale worldwide. The test reads up to 20,000 base pairs (vs. ~300 in standard sequencing), can replace up to 15 separate genetic tests in a single assay, simultaneously detects epigenetic modifications, and yields a 3% increase in diagnostic rate for rare diseases (validated in 1,000 patients and published in the New England Journal of Medicine). The center plans to perform ~5,000 long-read tests annually, roughly one-sixth of its total annual diagnostic volume. Additional specialty capabilities include continuous remimazolam sedation for endoscopy, bionic foot development with University of Twente, 3D-printed prosthetics in The Gambia, and extramural astrobiology research with the German Aerospace Center.

Name

Radboud university medical center

Legal name

Radboud university medical center

Website

https://radboudumc.nl

Company type

Public

Founded year

1951

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Radboudumc is a Dutch public academic medical center in Nijmegen (13,000 staff, ~30K inpatients and 400K outpatients yearly), providing tertiary care, pediatric medicine via the Amalia Children's Hospital, and clinical long-read genome sequencing for rare diseases.

Ownership category

akta.pro rank

Product category

Academic Medical Center

NAICS

General Medical and Surgical Hospitals (622110), General Medical and Surgical Hospitals (62211), Medical Laboratories (621511), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Medical Laboratories (8071)

akta.pro primary industry

Community & Regional General Hospitals (HLAFAAAB)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

Keywords

• Academic hospital care
• Clinical research
• Medical education
• Genomic diagnostics
• Specialized pediatric care

Headquarters

HQ city

Nijmegen

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Others

Revenue model

1. Healthcare service delivery: University medical center providing comprehensive healthcare services to patients. Revenue generated through Diagnosis Treatment Combinations (DBCs) under Dutch healthcare insurance system. Patient volumes include approximately 30,000 inpatients and 400,000 outpatients annually.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Radboud university medical center (Radboudumc) is a Dutch university medical center in Nijmegen delivering patient healthcare, biomedical research, and medical education. It treats approximately 30,000 inpatients and 400,000 outpatients annually and operates 665 beds across specialized care areas, including the Amalia Children's Hospital and clinical genetics.

Product overview

Radboud university medical center (Radboudumc) is an academic medical center in Nijmegen, Netherlands, offering integrated healthcare services, research, and education. The center provides patient care across multiple specialties including the Amalia Children's Hospital, conducts scientific research across various disciplines (such as genetics, genomics, pediatrics, infectious diseases, and biomedical technology), and offers academic training programs for students and researchers. The center collaborates with Radboud University on a joint campus.

Differentiator

Problem solved

Functional benefit

Brands

• Amalia Kinderziekenhuis: The Amalia Children's Hospital provides medical care for children and pregnant women, operating as a specialized children's hospital within Radboudumc.

Quantifiable outcome

• 3% increase in diagnostic yield for rare genetic disorders
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Medical Research Council Unit The GambiacoreStrategic or Co-development Partner · 8 July 2026Partnership in 3D printing pilot program for prosthetic socket production. Co-financed by European Union, implemented with technical support from University of Southampton and 3D Lab at Radboud UMC.
• National Rehabilitation Centre The GambiaminorStrategic or Co-development Partner · 8 July 2026Implementation partner for 3D printing prosthetic socket project in The Gambia, replacing traditional socket-making methods.
• FSHD EuropecoreStrategic or Co-development Partner · 20 June 2026Patient organization partnership for PaLaDIn project, creating patient-focused platform collecting data directly from patients with neuromuscular disorders. Linked to Radboudumc and partner in Project Mercury.
• Parent Project ItalycoreStrategic or Co-development Partner · 20 June 2026Lead organization of PaLaDIn consortium with international scope, with FSHD case study workstream co-led by FSHD Society and TREAT-NMD.
• FSHD SocietycoreStrategic or Co-development Partner · 20 June 2026Co-leader of FSHD case study workstream within PaLaDIn project, part of Project Mercury global patient-led initiative.
• TREAT-NMDcoreStrategic or Co-development Partner · 20 June 2026UK-based organization co-leading FSHD case study workstream within PaLaDIn project, supported by global network of neuromuscular field experts.
• Boston UniversitycoreStrategic or Co-development Partner · 16 June 2026Lead coordination of international research project TRAFFIC on cerebral amyloid angiopathy (CAA), funded by $9M Leducq Foundation grant. Network includes researchers from multiple US and European institutions combining brain imaging, laboratory research, and patient data.
• German Aerospace Center (DLR)minorStrategic or Co-development Partner · 15 June 2026Research collaboration investigating whether terrestrial microorganisms can survive in extraterrestrial conditions on Moon, Mars, and icy moons of Jupiter and Saturn.
• Radboud UniversitycoreStrategic or Co-development Partner · 9 March 2026Collaboration on choroideremia research as part of Radboud University and Radboudumc partnership, pursuing gene therapy and antisense oligonucleotides approaches.
• University of TwenteminorStrategic or Co-development Partner · 8 March 2026Joint development of bionic foot that mimics natural walking, supported by European SimBionics project with integrated sensors and battery for real-life testing.
• Maastricht University Medical CenterminorStrategic or Co-development Partner · 21 December 2025Initial research partner for TACTICAS pilot study on COPD exacerbation detection through voice recordings, with Radboudumc now collaborating on SPEAK mobile app development.
• Maastricht UMC+coreStrategic or Co-development Partner · 17 November 2025Collaborative partnership for long-read genome sequencing research and clinical implementation. Jointly developing and validating new genetic diagnostic tests for rare diseases. Research validated across 1,000 patients and published in New England Journal of Medicine.

Scale indicators5 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Erasmus MC: Rotterdam-based Dutch university medical center with comparable scale (~14,000 staff), research/teaching mission, and a similar academic-hospital operating model serving as a direct domestic peer within the eight-center NFU consortium.
• Amsterdam UMC: Merged AMC-VUmc Dutch university medical center with similar academic mission, multi-specialty clinical services, research output, and government-funded teaching hospital structure as Radboudumc.
• UMC Utrecht: Dutch university medical center sharing the same NFU academic-hospital classification, research-teaching-care integrated model, and pediatric and rare-disease programs comparable to Radboudumc.
• Maastricht UMC+: Dutch academic medical center and current strategic partner on the long-read genome sequencing program, providing a directly comparable model for clinical-academic integration and rare-disease diagnostics.
• Leiden University Medical Center (LUMC): Dutch university medical center with comparable academic hospital structure, rare-disease expertise, and NFU membership, serving a comparable patient population in western Netherlands.
• University Medical Center Groningen (UMCG): Northern Dutch academic medical center with similar scale, academic mission, and tertiary referral role; shares the Dutch UMC operating model and DBC reimbursement system with Radboudumc.

Broad incumbents

• Karolinska University Hospital: Swedish university hospital with comparable academic-medical-center mission, rare-disease and genomics programs, and Nordic public funding model — broader in geographic reach and research output than Radboudumc.
• Mayo Clinic: Largest US academic medical center with integrated research-clinical-education model, rare-disease diagnostics, and genomics leadership — broader in scale and global brand but a structurally analogous academic medical institution.
• Cleveland Clinic: US-based academic medical system with comparable tertiary referral base, research output, and specialty-care positioning — broader and more globally recognized but serving the same academic-clinical integrated function.

Others

• Pacific Biosciences: Provider of the HiFi long-read sequencing platform underpinning Radboudumc's rare-disease diagnostic program; while not a clinical peer, it is the core technology enabler for the institution's flagship clinical innovation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/radboudumc
• YouTubeyoutube.com/@radboudumc_
• Facebookfacebook.com/radboudumc
• LinkedInlinkedin.com/company/radboudumc
• Instagraminstagram.com/radboudumc

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Radboud university medical center